Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.

Dean M Robinson1, Gillian M Keating

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|April 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Dexmethylphenidate extended release (XR) effectively reduces attention-deficit hyperactivity disorder (ADHD) symptoms in children, adolescents, and adults. This once-daily formulation offers a consistent pharmacokinetic profile, demonstrating significant symptom improvement compared to placebo across multiple trials.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Dexmethylphenidate extended release (XR) is an oral formulation of d-methylphenidate (MPH).
  • It functions by inhibiting dopamine and norepinephrine reuptake.
  • This mechanism increases neurotransmitter concentrations in the extraneuronal space.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of dexmethylphenidate XR in treating ADHD.
  • To compare the pharmacokinetic profile of dexmethylphenidate XR to immediate-release formulations.
  • To assess ADHD symptom reduction in pediatric and adult populations.

Main Methods:

  • Four randomized, double-blind, placebo-controlled trials were conducted.
  • Participants included children, adolescents, and adults diagnosed with ADHD.

Related Experiment Videos

  • Efficacy was measured by ADHD symptom scores over treatment durations up to 7 weeks.

    • Main Results:

    • Once-daily dexmethylphenidate XR demonstrated greater efficacy than placebo in reducing ADHD symptom scores.
    • In pediatric crossover trials, dexmethylphenidate XR showed significant symptom reduction for up to 12 hours.
    • Adult trials indicated substantial symptom score reductions with dexmethylphenidate XR compared to placebo.

    Conclusions:

    • Dexmethylphenidate XR is an effective treatment for ADHD across pediatric and adult populations.
    • The extended-release formulation provides sustained symptom control with a favorable pharmacokinetic profile.
    • The drug was generally well-tolerated, exhibiting an adverse event profile consistent with MPH.